Organization
Innovative Medicines Canada
- Meetings this Parliament
- 98
- With MPs
- 37
- Since Nov 2021
- 279
- Active registrations
- 1
Most recent reported meeting: Sep 18, 2026.
Lobbying by Innovative Medicines Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Maggie Chi Liberal 4
- Karim Bardeesy Liberal 3
- Marjorie Michel Liberal 3
- Tom Kmiec Conservative 3
- Helena Jaczek Liberal 2
- Mélanie Joly Liberal 2
- Burton Bailey Conservative 1
- Jagsharan Singh Mahal Conservative 1
- Kurt Holman Conservative 1
- Matt Strauss Conservative 1
- John Zerucelli Liberal 1
- Charles Sousa Liberal 1
Institutions
- House of Commons32
- Health Canada (HC)22
- Innovation, Science and Economic Development Canada (ISED)21
- Finance Canada (FIN)10
- Treasury Board Of Canada Secretariat (TBS)7
- Privy Council Office (PCO)7
- Intergovernmental Affairs Secretariat (IGA)7
- Global Affairs Canada (GAC)7
Registrations in effect
In-house (organization) In effect since Sep 11, 2026
Filed by Bettina Hamelin, President and CEO
Lobbyists
-
Patricia Best · Vice-President, Government and Stakeholder Relations
Former designated public office holder
Formerly Senior Special Advisor, Office of the Minister of Finance, Minister of Finance (2014–2015)
Formerly Director of Communications, Minister's Office - Natural Resources Canada, Minister of National Resources Canada (2011–2012)
-
Agata Stankiewicz · Senior Director, Government Relations, Ontario
Former public office holder
Formerly Trade Commissioner, Toronto Office, Global Affairs Canada (2018–2018)
Formerly Policy Analyst, Office of International Affairs for the Health Portfolio, Public Health Agency of Canada (2016–2018)
Formerly Policy Analyst, Social Determinants and Science Integration Directorate, Public Health Agency of Canada (2012–2016)
Formerly Epidemiologist, Centre for Chronic Disease Prevention, Public Health Agency of Canada (2010–2012)
-
Bettina Hamelin · President and CEO
Former public office holder
Formerly Vice President, Research Partnerships, Natural Sciences and Engineering Research Council of Canada, Council of Canada (2015–2017)
- Brendan Lounsbery · General Counsel & Vice President, Legal, Compliance & Regulatory
-
Charles Brown · Director, Government Affairs, West
Former public office holder
Formerly Labour Market Economic Analyst, Economic Services, Employment and Immigration Canada (1989–1992)
- Greg Hein · Vice President, Strategy, Systems Transformation & Research
-
Hugh Scott · Executive Director, Strategic Alliances
Former public office holder
Formerly Legislative Assistant to Albina Guarnieri, M.P. - Parliamentary Secretary to the Minister of Canadian Heritage, Parliament Hill Office, Canadian Heritage (1994–1998)
- Jennifer Buckley · Senior Director, Regulatory Affairs and Clinical Research Transformation
- Joe Farago · Executive Director, Market Access
- Kristian LeBlanc · Senior Director, Atlantic, Government Relations
-
Michael Dietrich · Vice President, Market Access Policy
Former public office holder
Formerly Jr. Research Analyst, Industrial Analysis, Industry Canada (2004–2004)
-
Sophie Normand · Director, Federal Government Relations
Former public office holder
Formerly Social Media Coordinator, Communications Directorate, Senate of Canada (2020–2021)
Formerly Social Media and Special Projects Coordinator, Office of the Speaker of the House of Commons, Parliament of Canada (2018–2019)
Formerly Director of Events (acting), Office of the Speaker of the House of Commons, Parliament of Canada (2018–2018)
Formerly Administrative Assistant, Office of the Speaker of the House of Commons, Parliament of Canada (2017–2018)
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (23)Hide details
- Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
- Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry.
- Federal policies that relate to possible models of pharmacare
- Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
- National Strategy for Drugs for Rare Diseases
- World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
- World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry
- World Health Organization (WHO) issues concerning the biopharmaceutical industry
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
- Income Tax Act as it relates to biopharmaceutical products
- Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
- Free trade agreements as they relate to the biopharmaceutical industry
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
Registration 957857-371-135. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Bettina Hamelin (157), Pamela Fralick (85), David Renwick (37).
-
Reported by Bettina Hamelin · In-house (organization)
- Philip Jennings · Deputy Minister of Innovation, Science and Economic Development Canada (ISED), Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Maggie Chi · Member of Parliament
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 7 moreShow fewer
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
-
Reported by Bettina Hamelin · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
and 6 moreShow fewer
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Justine Frame · Policy Advisor, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Read more
Free trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
-
Reported by Bettina Hamelin · In-house (organization)
- John Zerucelli · Member of Parliament, and Secretary of State for Labour
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Helena Jaczek · Member of Parliament
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Tom Kmiec · Member of Parliament
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Maggie Chi · Member of Parliament, Parliamentary Secretary to Minister of Health
- Nora Draper · Assistant to the Parliamentary Secretary to Minister of Health, Health Canada (HC)
- Sara Kasum · Parliamentary Affairs Advisor, Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Celia Lourenco · Associate Assistant Deputy Minister, Health Canada (HC)
- Daniel MacDonald · Director General, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Karim Bardeesy · Member of Parliament
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs and One Canadian Economy, Privy Council Office (PCO)
- Marjorie Michel · Minister of Health, Health Canada (HC)
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
and 7 moreShow fewer
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
- Martin Moen · Assistant Associate Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
- Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Chanel Sterie · Senior Policy Advisor, Public Services and Procurement Canada (PSPC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Miro Froehlich · Director of Policy, Privy Council Office (PCO)
- Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Maggie Chi · Member of Parliament, Parliamentary Secretary to Minister of Health
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
-
Reported by Bettina Hamelin · In-house (organization)
- Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Read more
-
Reported by Bettina Hamelin · In-house (organization)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- François Rivest · Director General, Export Support Bureau, Global Affairs Canada (GAC)
- Natalie Zakhem · Trade Commissioner, Global Affairs Canada (GAC)
- Elizabeth Reid · Senior Trade Commissioner, Global Affairs Canada (GAC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
- Sara Kasum · Parliamentary Affairs Advisor to the Minister of Health, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Jagsharan Singh Mahal · Member of Parliament
Free trade agreements as they relate to the biopharmaceutical industry
-
Reported by Bettina Hamelin · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Free trade agreements as they relate to the biopharmaceutical industry Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
-
Reported by Bettina Hamelin · In-house (organization)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister of Health, Health Canada (HC)
- Justine Frame · Policy Advisor, Office of the Minister of Health, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Read more
Free trade agreements as they relate to the biopharmaceutical industry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.